ESR2 and breast cancer: This view of ERβ as purely suppressive in BC is defective, with a growing body of evidence reporting elevated ERβ expression as a predictor of poor prognosis and reduced disease-free survival (DFS) in women with ERα+ BC who underwent ET [10, 11].